Instil Bio
56 hedge funds and large institutions have $1.62B invested in Instil Bio in 2021 Q1 according to their latest regulatory filings, with 56 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
2.58% more ownership
Funds ownership: 0% → 2.58% (+2.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$320M |
| 2 |
CI
CPMG Inc
Dallas,
Texas
|
+$218M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$183M |
| 4 |
VA
VR Adviser
New York
|
+$176M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$125M |
Top Sellers
TIL Hedge Fund Activity: Q1 2021 in Review
56 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Instil Bio (TIL) for Q1 2021, worth a combined $1.62B.
Buyers outnumbered sellers: 56 funds opened new TIL positions and 0 closed out — a net gain of 56 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $320M.
- 56 institutional investors held Instil Bio (TIL) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $1.62B of Instil Bio stock for Q1 2021.
- 56 funds opened new Instil Bio positions in Q1 2021 and 0 closed out, a net change of +56 holders.
- The largest Instil Bio buyer in Q1 2021 was Vivo Capital, an estimated $320M added.
Based on aggregated 13F filings for Q1 2021.